Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danzhiqinge is a Traditional Chinese Medicine (TCM) tablet formulation developed by Tianjin University of Traditional Chinese Medicine for the treatment of menopausal syndrome. It is specifically indicated for patients presenting with the TCM pattern of kidney yin-yang deficiency. The drug is currently being evaluated in Phase 2 clinical trials in China to assess its efficacy, safety, and optimal dosage in women aged 40–55 years experiencing menopausal symptoms. As a TCM product, it likely contains multiple botanical extracts intended to modulate the neuroendocrine system and alleviate symptoms such as hot flashes, insomnia, and mood changes associated with the menopausal transition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danzhiqinge.